Moderna’s Huge Initial Public Offering Was Based on Disputed Claim That mRNA Is ‘Impermanent’

Coronavirus vaccine maker Moderna Therapeutics issued an initial public offering (IPO) for its stock in 2018 that made now-disputed statements in an attempt to portray messenger RNA (mRNA) as an “impermanent” ingredient that does not change “genes or cell DNA.” But research has found that mRNA, which is a main ingredient in Moderna and also Pfizer-BioNTech Coronavirus injections, permanently affects and alters the human body.

Moderna’s IPO spoke of “transformative medicines based on messenger RNA.” The Moderna IPO in 2018 was reported at the time to be the biggest initial public offering in the history of the biotech sector, with underwriters represented by Morgan Stanley, Goldman Sachs, Barclays Capital, JP Morgan and other major financial firms. As NATIONAL FILE reported, the National Institutes of Health (NIH) has a financial stake in the Moderna Coronavirus vaccine. NATIONAL FILE also reported that the University of Pennsylvania — which hosts and funds Joe Biden’s think tank — profits from the sale of Pfizer-BioNTech and Moderna Coronavirus vaccines, and also profits from the Biden FDA’s approval of the injections, marking a massive conflict of interest. Bill Gates’ foundation has long been providing massive multi-million dollar funding to Moderna for mRNA technology, as evidenced by a report from 2016. Moderna absorbed more than half a billion dollars in losses in 2019. Then came Coronavirus, and the Moderna Coronavirus vaccine.

Researcher Dr. Charles Hoffe, in a Zoom call meeting, stated, on the topic of the mRNA-based Coronavirus injection: “These vaccines are a vast number of little messenger RNA strands. The Moderna vaccine has 40 trillion messenger RNA molecules per vaccine dose. 40 trillion…So I believe that these people blocked up thousands and thousands of capillaries in their lungs, in these six people. So I believe these people now have permanently damaged lungs because…I mean, that’s why they get out of breath.”

“We are creating a new category of transformative medicines based on messenger RNA, or mRNA, to improve the lives of patients. From the beginning, we designed our strategy and operations to realize the full potential value and impact of mRNA over a long time horizon across a broad array of human diseases,” the Moderna IPO stated, noting that “mRNA transfers the instructions stored in DNA to make the proteins required in every living cell. Our approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease. A schematic of the central role of mRNA in making proteins is shown in the figure below,” the Moderna IPO stated in 2018.

“Finally, mRNA is impermanent. mRNAs produce proteins for a defined and biologically-regulated period of time without risk of changing genes or cell DNA. If dosing of mRNA stops, protein production will stop and the biological effects generally can be reversed,” Moderna’s IPO stated on page 124, which is now a heavily disputed statement.